Hologic reported a solid start to fiscal year 2026, with revenue slightly exceeding guidance and non-GAAP EPS at the high end of expectations. The company's Breast Health and Molecular Diagnostics segments showed strong growth, offsetting a decline in Diagnostics revenue. Management expressed confidence in achieving full-year guidance.

Hologic delivered a robust performance in the fourth quarter of fiscal 2025, with total revenue reaching $1,049.5 million, marking a 6.2% increase year-over-year. Both GAAP and non-GAAP diluted EPS saw significant growth, rising by 9.2% and 11.9% respectively. The company also generated strong cash flow from operations and maintained a healthy financial position.

Hologic delivered a solid third quarter in fiscal 2025, with revenue of $1,023.8 million and non-GAAP diluted EPS of $1.08, both surpassing guidance. The company saw growth in Diagnostics and Surgical segments, with a continued rebound in Breast Health expected to drive future growth.

Hologic delivered Q2 2025 results that met revenue and adjusted EPS guidance, despite a GAAP net loss driven by significant intangible asset impairment charges.

Hologic announced financial results for the first quarter of fiscal 2025, reporting revenues of $1,021.8 million, a 0.9% increase year-over-year. GAAP diluted EPS was $0.87, while non-GAAP diluted EPS reached $1.03, hitting the high end of guidance. The company also completed the acquisition of Gynesonics, expanding its surgical portfolio.

Hologic reported a strong fiscal fourth quarter in 2024, with a 4.5% increase in revenue to $987.9 million. GAAP diluted EPS was $0.76, and non-GAAP diluted EPS was $1.01. The company expects strong execution of its broad-based growth strategy in fiscal 2025.

Hologic announced its financial results for the fiscal third quarter ended June 29, 2024, with revenue of $1,011.4 million, a 2.7% increase, and GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $1.06. The company's performance was driven by higher sales in Molecular Diagnostics, Breast Imaging, and Surgical.

Hologic announced its Q2 2024 financial results, with revenue reaching $1,017.8 million. The company's GAAP diluted EPS was $0.72, and non-GAAP diluted EPS was $1.03. Revenue and non-GAAP diluted EPS exceeded the company's guidance. Total company organic revenue, excluding COVID-19, grew by 4.9% in constant currency.

Hologic reported a revenue of $1,013.1 million for the first quarter of fiscal year 2024, a decrease of 5.7% compared to the prior year, but exceeded their guidance. GAAP diluted EPS was $1.03 and non-GAAP diluted EPS was $0.98, also exceeding guidance. Total organic revenue growth excluding COVID-19 was 5.2% in constant currency.

Hologic's Q4 2023 revenue reached $945.3 million with a GAAP diluted EPS of $0.37 and a non-GAAP diluted EPS of $0.89. The company's organic revenue growth excluding COVID-19 was 16.7% in constant currency. They expect broad-based strong performance in fiscal year 2024.

Hologic reported a revenue of $984.4 million for Q3 2023. Despite a decrease in overall revenue due to lower COVID-19 assay sales, the company experienced double-digit growth across all franchises excluding COVID-19 impact. The company exceeded its prior revenue guidance and demonstrated strong cash flow from operations.

Hologic reported a decrease in revenue by 28.5% to $1,026.5 million, primarily due to lower COVID-19 assay sales. Excluding COVID-19 revenues, total organic revenue grew by 20.2%. The company's GAAP diluted EPS was $0.87, and non-GAAP diluted EPS was $1.06, both exceeding guidance. Hologic raised its fiscal year 2023 revenue and EPS guidance.

Hologic reported a decrease in revenue by 27.0% to $1,074.2 million, but exceeded revenue expectations. Diagnostics and Surgical businesses experienced double-digit organic revenue growth ex. COVID-19. The company increased its full-year fiscal 2023 guidance for both revenue and EPS.

Hologic's Q4 2022 revenue reached $953.3 million, a decrease of 27.6% compared to the previous year, driven by lower COVID-19 assay sales and supply chain challenges. GAAP diluted EPS was $0.47, while Non-GAAP diluted EPS was $0.82, both exceeding expectations. The company anticipates strong growth in core businesses for fiscal year 2023.

Hologic's Q3 2022 financial results exceeded expectations, with revenue of $1.003 billion and GAAP diluted EPS of $0.90. The company experienced a decrease in revenue compared to the prior year, primarily driven by lower international sales of COVID-19 assays and supply chain challenges in the Breast Health business. However, the base Diagnostics and Surgical franchises showed strong growth.

Hologic's Q2 2022 financial results exceeded expectations, with revenue of $1.436 billion and GAAP diluted EPS of $1.80. The company raised its full-year revenue and EPS guidance, driven by the health and diversity of its base businesses and diagnostic testing for COVID-19.

Hologic reported a revenue of $1.471 billion, a decrease of 8.6% compared to the prior year, driven by lower sales of COVID-19 assays. However, excluding COVID-19 revenue, organic revenue grew by 9.0%. GAAP diluted EPS was $1.95, and non-GAAP diluted EPS was $2.17, both significantly exceeding expectations. The company also significantly increased its full-year revenue and EPS guidance.

Hologic announced strong Q4 2021 results, with revenue exceeding expectations. The company's diversified business, particularly in women's health, drove growth despite a decline in COVID-19 assay sales compared to the prior year period. Hologic is guiding for continued growth in fiscal year 2022, driven by core women’s health businesses and contributions from COVID-19 testing.

Hologic reported strong financial results for the third quarter of fiscal year 2021, with revenue increasing 42.0% to $1.168 billion and GAAP diluted EPS reaching $1.04. The company finalized the Mobidiag acquisition and experienced growth in its base businesses.

Hologic reported a strong second quarter in fiscal year 2021, with organic revenue doubling due to recovery in base businesses and response to the COVID-19 pandemic. The company completed three acquisitions and announced another, expecting accelerated growth post-pandemic.

Hologic's Q1 2021 revenue reached $1.61 billion, an 89.3% increase year-over-year, driven by strong performance in the Diagnostics division and growth in Breast Health and Surgical businesses. The company reported GAAP diluted EPS of $2.50 and non-GAAP diluted EPS of $2.86.

Hologic, Inc. reported strong financial results for the fourth quarter of fiscal year 2020, with revenue increasing by 55.6% to $1.347 billion. The company's performance was driven by strong sales of COVID-19 tests, which offset declines in other businesses. GAAP diluted EPS was $1.88, and non-GAAP diluted EPS was $2.07.

Hologic's Q3 2020 results showed a revenue decrease of 3.5% due to the Cynosure divestiture, but organic revenue grew by 7.7%. Molecular Diagnostics revenue increased significantly due to high demand for COVID-19 tests. The company launched a new ultrasound system in its Breast Health division and repaid $250 million of debt.

Hologic's second quarter revenue decreased by 7.6% due to the Cynosure divestiture, but organic revenue increased by 0.5%. The company reported GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.57. Hologic is also introducing a second high-throughput Coronavirus test for its Panther® platform.